Skip directly to local search Skip directly to A to Z list Skip directly to navigation Skip directly to site content Skip directly to page options
CDC Home

Volume 12, Number 6—June 2006

Perspective

Host Range Restriction and Pathogenicity in the Context of Influenza Pandemic

Gabriele Neumann* and Yoshihiro Kawaoka*†‡Comments to Author 
Author affiliations: *University of Wisconsin-Madison, Madison, USA; †University of Tokyo, Tokyo, Japan; ‡Japan Science and Technology Agency, Saitama, Japan

Suggested citation for this article

Abstract

Influenza A viruses cause pandemics at random intervals. Pandemics are caused by viruses that contain a hemagglutinin (HA) surface glycoprotein to which human populations are immunologically naive. Such an HA can be introduced into the human population through reassortment between human and avian virus strains or through the direct transfer of an avian influenza virus to humans. The factors that determine the interspecies transmission and pathogenicity of influenza viruses are still poorly understood; however, the HA protein plays an important role in overcoming the interspecies barrier and in virulence in avian influenza viruses. Recently, the RNA polymerase (PB2) protein has also been recognized as a critical factor in host range restriction, while the nonstructural (NS1) protein affects the initial host immune responses. We summarize current knowledge of viral factors that determine host range restriction and pathogenicity of influenza A viruses.

Of the 3 types of influenza viruses (A, B, and C), only influenza A viruses are established in animals other than humans. Influenza pandemics are caused by viruses that have a hemagglutinin (HA) to which most humans have no immune memory. The strains of the 1957 Asian and 1968 Hong Kong pandemics had HAs derived from an avian virus. Although little information exists about avian influenza viruses at the time of the Spanish influenza pandemic, the HA of the virus responsible for that outbreak is also thought to be of avian origin. Since avian influenza viruses do not replicate efficiently in humans and nonhuman primates, they must overcome host range restriction for the avian virus HA to be introduced into human populations. The molecular basis for host range restriction is not well understood; however, HA plays a key role in the restriction of interspecies transmission.

The Spanish influenza was among the most devastating infectious diseases in history. At least 20 million people died worldwide. Antimicrobial agents were not available in 1918; however, existing evidence suggests that this high death toll was due to the extreme virulence of the virus. Although all 8 RNA segments of the Spanish influenza virus have been sequenced, these sequences offer no explanation for the high virulence. The Spanish influenza exemplifies how the magnitude of a pandemic can be determined by the pathogenicity of the virus.

In this review, we focus on 2 properties of influenza A viruses as they relate to pandemics, host range restriction and pathogenicity. Viral factors that affect these properties are examined.

Viral Proteins Responsible for Host Range Restriction

Viral Glycoproteins

The HA protein mediates virus binding to sialic acid (SA)–containing host cell surface molecules and promotes the release of viral ribonucleoprotein complexes through membrane fusion. By contrast, the sialidase activity of the neuraminidase (NA) protein removes SA to liberate newly synthesized viruses from infected cells. Thus, efficient virus replication requires the balanced actions of HA receptor-binding specificity and NA sialidase activity.

HA Receptor Specificity

Influenza virus infectivity is influenced by 2 entities: SA species (N-acetylneuraminic acid [NeuAc] and N-glycolylneuramic acid [NeuGc]) and the type of linkage to galactose (sialyloligosaccharides terminated by SA linked to galactose by an α2,6 linkage [Acα2,6Gal] or an α2,3 linkage [Acα2,3Gal]) on the host cell surface. Human influenza viruses preferentially recognize sialyloligosacchrides containing SAα2,6Gal (1,2), matched by mainly NeuAcα2,6Gal linkages on the epithelial cells of the human trachea (3). By contrast, avian viruses preferentially recognize SAα2,3Gal sialic acids (1,2), in accordance with the predominance of sialyoligosaccharides with SAα2,3Gal linkages on the epithelial cells of duck intestine. The epithelial cells of pig trachea contain both types of SAs and both types of linkages (4), which likely explains the high susceptibility of these animals to both human and avian influenza viruses (5). Pigs may therefore serve as a "mixing vessel" for reassortment between these 2 viruses and the source of pandemic strains, although no evidence exists that the 1957 or 1968 pandemic viruses originated in pigs.

Despite these differences in receptor specificity, avian viruses can infect humans and have caused lethal infections (68). This fact may be explained by the recent finding that in differentiated cultures of human tracheobronchial epithelium, α2,3-linked SAs were found on ciliated cells, whereas α2,6-linked SAs were present on nonciliated cells (9). The prevalence of cells that possess α2,6 and/or α2,3-linked SAs in the lower respiratory tract remains unknown; however, ciliated cells support avian virus infection. Despite the presence of α2,6-linked SA-bearing cells in differentiated human tracheobronchial epithelium, viruses with avian-type receptor specificity can infect humans, since the index 1997 H5N1 virus isolated from a human preferentially recognized an avian receptor (10). Nevertheless, for efficient human-to-human transmission, HA derived from an avian virus must preferentially recognize the human receptor. This notion is supported by the finding that the earliest isolates in the 1918 (11,12), 1957, and 1968 pandemics preferentially recognized NeuAcα2,6Gal–containing sialyloligosaccharides (13), even though their HAs were derived from avian viruses. Conversion of receptor specificity from SAα2,3Gal to SAα2,6Gal may therefore be critical for generating pandemic influenza viruses.

Sequence comparison, receptor specificity assays, and crystallographic analysis have identified amino acid residues that determine receptor specificity: Gln-226 (found in avian viruses) determines specificity for SAα2,3Gal, whereas Leu-226 correlates with SAα2,6Gal specificity in human H2 and H3, but not H1, viruses (2,13). In all human viruses (with the few exceptions of early isolates from the Asian influenza outbreak [13]), Leu-226 is associated with Ser-228, while Gln-226 is associated with Gly-228 in avian viruses. For H1 viruses, Asp-190 (found in human and swine virus isolates) or Glu-190 (found in avian virus isolates) determines preferential binding to α2,6 or α2,3 linkages, respectively (1114).

Land-based poultry are thought to play a critical role in the emergence of pandemic influenza viruses. Compared to H5N1 viruses isolated from aquatic birds, those isolated from chickens have significantly lower affinity for NeuAcα2,3Gal (10), similar to human virus isolates; however, H5N1 chicken isolates have not acquired preferential specificity for NeuAcα2,6Gal. H5N1 chicken isolates with reduced avian receptor specificity share 2 characteristic features of human viruses, namely, an additional glycosylation site in the globular head region of HA and a deletion in the NA stalk (see below). Similarly, the receptor specificity of H9N2 viruses isolated from land-based poultry, but not of those isolated from aquatic birds, is similar to that of human isolates (15). Hence, land-based poultry may serve as an intermediate host that facilitates the conversion of avian to human-type receptors. Avian viruses in land-based poultry may, therefore, pose a greater threat to humans than previously thought.

NA Properties

Since efficient release of virus from infected cells requires the removal of SA by NA, the receptor-binding and receptor-destroying properties of HA and NA, respectively, must be balanced. When an avian virus with an N2 NA was introduced into the human population, its SAα2,6 cleavage activity increased (16,17), which suggests it had adapted to the SAα2,6 receptor specificity of human HAs.

The NA stalk, which separates the head region with the enzymatic center from the transmembrane and cytoplasmic domains, varies in sequence and length, depending on the virus (18). Typically, shortened stalks result in less efficient virus release since the active site in the head region cannot efficiently access its substrate (19,20). However, naturally occurring avian viruses with shortened stalks are virulent in poultry, and the 1997 H5N1 viruses isolated from patients in Hong Kong (which are believed to have been transmitted to humans from poultry) are characterized by a deletion in the NA stalk (10). Moreover, most recent highly pathogenic H5N1 viruses isolated from terrestrial poultry possess short NA stalks (21).

In avian species, the intestinal tract is the primary site of replication, whereas in humans, influenza virus replication is typically restricted to the respiratory tract. The NA activity of avian H1N1 viruses is more resistant to the low pH environment in the upper digestive tract than is its human or swine-derived counterpart (22). In line with this finding, highly pathogenic H5N1 viruses can replicate in the human intestine, causing gastrointestinal symptoms (23), and are shed in large amounts in stool.

Internal Proteins

Classical coinfection experiments, or reverse genetics experiments that tested multiple gene combinations of 2 parental viruses, suggest that the genes encoding the "internal proteins"—namely, RNA polymerase (PB2, PB1, PA), nucleoprotein (NP), matrix protein (M1, M2), and nonstructural protein (NS1, NS2/NEP)—also contribute to host range. The contribution of individual proteins to host range restriction, however, likely varies, depending on the test system and the virus strains under investigation.

PB2

PB2 is a component of the viral polymerase complex and, as such, is essential for viral replication. The 1997 H5N1 human virus isolates in Hong Kong have been divided into 2 groups on the basis of their pathogenicity in mice; this classification also generally corresponds to disease severity in humans (24,25). Reverse genetics studies have shown that Lys at position 627 of PB2 (found in all human isolates) determines high pathogenicity in mice, while Glu at this position (found in all avian isolates) determines low pathogenicity (26). However, the nature of the amino acid at position 627 of PB2 does not affect the cell tropism of the virus but rather its replicative ability in mice and probably in humans.

Several other findings underline the importance of residue 627 of PB2: 1) an H7N7 virus isolated from a patient with fatal pneumonia in the Netherlands in 2003 contained Lys at this position, in contrast to viruses isolated from nonfatal cases and from chickens (27); 2) some of the H5N1 viruses isolated from patients in Vietnam are characterized by Lys-627 in PB2 (28); 3) a single reassortant virus bearing an avian virus PB2 gene against a human virus background replicated efficiently in avian but not human cells, a feature that could be traced to the nature of the amino acid at position 627 of PB2 (29); and 4) ribonucleoprotein complexes reconstituted from human or avian polymerase and NP proteins identified residue 627 of PB2 as the major determinant of replication efficiency in mammalian cells (30). Collectively, these findings suggest that a Glu-to-Lys mutation at position 627 of the PB2 protein allows avian viruses to efficiently grow in humans and implicates Lys at this position as an important host range determinant.

Other Components of the Replication Complex

In addition to PB2, the remaining 2 polymerase proteins (PB1 and PA) and the nucleoprotein NP may also contribute to host range. In a minireplicon system, replication in mammalian cells was more efficient with avian than with human virus PB1 proteins (30), which suggests that avian PB1 may have greater activity that could provide a replicative advantage in mammalian systems. This scenario is especially appealing in light of the finding that both the 1957 and 1968 pandemic viruses possessed avian PB1 genes, in addition to avian HA, NA, or both genes (31,32). In one study, however, an avian PB1 gene severely restricted replication of a human virus in mammalian cells and squirrel monkeys (33). These findings seem to contradict a role of avian PB1 in replication in mammalian cells. PA and NP proteins have also been implicated in host range restriction; for example, an avian virus NP segment against a background of a human virus resulted in attenuation in squirrel monkeys (33). However, because of the limited data available, whether these findings indicate a contribution of these gene products to host range restriction or simply reflect incompatibility among the viral gene segments is unclear.

M Segment

Segment 7 of influenza A viruses encodes the M1 matrix and the M2 ion channel proteins. In coinfection experiments that selected for reassortants containing a human virus M gene and an avian virus HA gene, the M segment of an early human virus (A/PR/8/34, H1N1) cooperated efficiently with avian virus HAs, whereas M segments derived from more recent isolates have gradually lost this ability (34). This finding may suggest that currently circulating human viruses are less likely to reassort with avian viruses than their predecessors. If this is the case, the risk for a global pandemic caused by reassortants possessing avian HA, NA, or both segments against a human virus background would be reduced.

Molecular Basis of Pathogenicity

HA Cleavability

The HA protein is synthesized as a precursor protein that is cleaved into 2 subunits (HA1 and HA2) by host cell proteases. HA cleavage is a prerequisite for fusion of the viral and endosomal membranes and, therefore, for viral infectivity (35). Low pathogenic avian influenza viruses possess a single Arg residue at the cleavage site, recognized by extracellular, trypsinlike proteases. These proteases are thought to be secreted only by cells of the respiratory and intestinal tract and consequently limit infections to these organs. By contrast, highly pathogenic avian viruses possess multiple basic amino acids at the cleavage that are recognized by ubiquitous, intracellular, subtilisin-like proteases that thus trigger systemic infection. In addition, HA cleavability is affected by the absence or presence of a carbohydrate side chain near the cleavage site that may interfere with the accessibility of host proteases to the cleavage site (36). The acquisition of a highly cleavable HA converted an avirulent strain to virulence in Pennsylvania in 1983 (H5N2), Mexico in 1994 (H5N2), Italy in 1997 (H7N1), Chile in 2002 (H7N3), and Canada in 2004 (H7N3) (Table). HA cleavability is, therefore, considered the major determinant of tissue tropism of avian influenza viruses (41). This correlation seems to extend to humans, since all avian viruses that have killed humans possess a highly cleavable HA (6,7,27), and an H5N1 mutant virus whose HA cleavage site had been changed to an avirulent type was attenuated in mice (26).

Role of NS1 in Antagonizing Cellular Immune Responses

Pathogenesis depends partly on the ability of a virus to evade or suppress the host immune response. The NS1 protein, encoded by segment 8, plays a central role in this process by counteracting the cellular interferon (IFN) response in a 2-pronged approach: 1) by binding to double-stranded RNA, thereby suppressing the activation of double-stranded RNA-activated protein kinase, a known stimulator of type I IFN, and 2) by preventing the activation of transcription factors such as ATF-2/c-Jun, NFκB, and IRF-3/5/7, all of which stimulate IFN production (42,43). The NS gene of the 1918 Spanish flu blocked the expression of IFN-regulated genes in human cells more efficiently than did the NS gene of the A/PR/8/34 (H1N1) virus (44), which suggests that the NS genes of highly pathogenic viruses may be more proficient in counteracting the host immune response than those of less pathogenic viruses.

Viruses containing the NS gene of the 1997 H5N1 virus are potent inducers of proinflammatory cytokine genes, particularly tumor necrosis factor-α (TNF-α) and IFN-β in human primary monocyte-derived macrophages (45). Similarly, 2003 human H5N1 isolates induce high levels of proinflammatory cytokines in primary human macrophages (46). These in vitro findings are substantiated by reports of unusually high serum concentrations of chemokines in patients infected with H5N1 influenza viruses. High levels of macrophage-derived chemokines and cytokines were also induced by a recombinant virus containing a gene segment of the 1918 Spanish flu; in this case, however, the HA segment stimulated the increased levels of chemokines and cytokines (14,47). This upregulation of cytokine function at later phases of infection may account for the unusual clinical signs and symptoms and the degree of disease severity associated with human infections of highly pathogenic influenza viruses.

Highly pathogenic H5N1 viruses not only trigger the overproduction of proinflammatory cytokines but also are resistant to the antiviral effects of IFN and TNF-α. Pretreatment of porcine lung epithelial cells with IFN-α, IFN-γ, or TNF-α has no effect on the replication of a recombinant human H1N1 virus possessing the NS gene of the 1997 H5N1 virus but abolishes replication of the parental human H1N1 virus (48,49). Resistance to the antiviral effects of IFN and TNF-α is associated with glutamic acid at position 92 of the NS1 protein, as demonstrated by reverse genetics studies. These in vitro data extend to in vivo findings, since pigs infected with a virus containing Glu-92 in NS1 experience higher virus titers and body temperatures than those infected with a control virus (48,49). Collectively, these findings indicate that NS1 induces a cytokine imbalance that likely contributes to the extreme pathogenicity of avian influenza viruses in humans.

Conclusions

One might speculate that the next pandemic may be caused by highly pathogenic H5N1 viruses that acquire the ability to be efficiently transmitted among humans, or by H9N2 viruses, which are as prevalent as H5N1 viruses in Asia and in some cases already recognize human receptors. Further investigation of the molecular basis of host range restriction is therefore important. In addition, a better understanding of the mechanisms and consequences of chemokine/cytokine imbalance caused by highly pathogenic avian viruses is essential, as is a greater appreciation for the contributions of other viral properties, such as replicative ability, to pathogenesis.

Dr Neumann is a research associate professor at the University of Wisconsin-Madison, Madison, Wisconsin. Her research interests are the pathogenicity of influenza and Ebola viruses and the development of reverse genetics techniques for negative-strand RNA viruses.

Dr Kawaoka is a professor at the University of Wisconsin-Madison and at the University of Tokyo, Tokyo, Japan. His research focuses on the molecular biology and pathogenesis of influenza and Ebola viruses.

References

  1. Rogers GN, Paulson JC. Receptor determinants of human and animal influenza virus isolates: differences in receptor specificity of the H3 hemagglutinin based on species of origin. Virology. 1983;127:36173. DOIPubMed
  2. Rogers GN, Paulson JC, Daniels RS, Skehel JJ, Wilson IA, Wiley DC. Single amino acid substitutions in influenza haemagglutinin change receptor binding specificity. Nature. 1983;304:768. DOIPubMed
  3. Couceiro JN, Paulson JC, Baum LG. Influenza virus strains selectively recognize sialyloligosaccharides on human respiratory epithelium; the role of the host cell in selection of hemagglutinin receptor specificity. Virus Res. 1993;29:15565. DOIPubMed
  4. Ito T, Couceiro JN, Kelm S, Baum LG, Krauss S, Castrucci MR, Molecular basis for the generation in pigs of influenza A viruses with pandemic potential. J Virol. 1998;72:736773.PubMed
  5. Kida H, Ito T, Yasuda J, Shimizu Y, Itakura C, Shortridge KF, Potential for transmission of avian influenza viruses to pigs. J Gen Virol. 1994;75:21838. DOIPubMed
  6. Claas EC, Osterhaus AD, Van Beek R, de Jong JC, Rimmelzwaan GF, Senne DA, Human influenza A H5N1 virus related to a highly pathogenic avian influenza virus. Lancet. 1998;351:4727. DOIPubMed
  7. Subbarao K, Klimov A, Katz J, Regnery H, Lim W, Hall H, Characterization of an avian influenza A (H5N1) virus isolated from a child with a fatal respiratory illness. Science. 1998;279:3936. DOIPubMed
  8. Fouchier RA, Schneeberger PM, Rozendaal FW, Broekman JM, Kemink SA, Munster V, Avian influenza A virus (H7N7) associated with human conjunctivitis and a fatal case of acute respiratory distress syndrome. Proc Natl Acad Sci U S A. 2004;101:135661. DOIPubMed
  9. Matrosovich MN, Matrosovich TY, Gray T, Roberts NA, Klenk HD. Human and avian influenza viruses target different cell types in cultures of human airway epithelium. Proc Natl Acad Sci U S A. 2004;101:46204. DOIPubMed
  10. Matrosovich M, Zhou N, Kawaoka Y, Webster R. The surface glycoproteins of H5 influenza viruses isolated from humans, chickens, and wild aquatic birds have distinguishable properties. J Virol. 1999;73:114655.PubMed
  11. Gamblin SJ, Haire LF, Russell RJ, Stevens DJ, Xiao B, Ha Y, The structure and receptor-binding properties of the 1918 influenza hemagglutinin. Science. 2004;303:183842. DOIPubMed
  12. Stevens J, Corper AL, Basler CF, Taubenberger JK, Palese P, Wilson IA. Structure of the uncleaved human h1 hemagglutinin from the extinct 1918 influenza virus. Science. 2004;303:186670. DOIPubMed
  13. Matrosovich M, Tuzikov A, Bovin N, Gambaryan A, Klimov A, Castrucci MR, Early alterations of the receptor-binding properties of H1, H2, and H3 avian influenza virus hemagglutinins after their introduction into mammals. J Virol. 2000;74:850212. DOIPubMed
  14. Kobasa D, Takada A, Shinya K, Hatta M, Halfmann P, Theriault S, Enhanced virulence of influenza A viruses with the haemagglutinin of the 1918 pandemic virus. Nature. 2004;431:7037. DOIPubMed
  15. Matrosovich MN, Krauss S, Webster RG. H9N2 influenza A viruses from poultry in Asia have human virus-like receptor specificity. Virology. 2001;281:15662. DOIPubMed
  16. Baum LG, Paulson JC. The N2 neuraminidase of human influenza virus has acquired a substrate specificity complementary to the hemagglutinin receptor specificity. Virology. 1991;180:105. DOIPubMed
  17. Kobasa D, Kodihalli S, Luo M, Castrucci MR, Donatelli I, Suzuki Y, Amino acid residues contributing to the substrate specificity of the influenza A virus neuraminidase. J Virol. 1999;73:674351.PubMed
  18. Blok J, Air GM. Variation in the membrane-insertion and "stalk" sequences in eight subtypes of influenza type A virus neuraminidase. Biochemistry. 1982;21:40017. DOIPubMed
  19. Els MC, Air GM, Murti KG, Webster RG, Laver WG. An 18-amino acid deletion in an influenza neuraminidase. Virology. 1985;142:2417. DOIPubMed
  20. Luo G, Chung J, Palese P. Alterations of the stalk of the influenza virus neuraminidase: deletions and insertions. Virus Res. 1993;29:14153. DOIPubMed
  21. Li KS, Guan Y, Wang J, Smith GJ, Xu KM, Duan L, Genesis of a highly pathogenic and potentially pandemic H5N1 influenza virus in eastern Asia. Nature. 2004;430:20913. DOIPubMed
  22. Takahashi T, Suzuki Y, Nishinaka D, Kawase N, Kobayashi Y, Hidari KI, Duck and human pandemic influenza A viruses retain sialidase activity under low pH conditions. J Biochem. 2001;130:27983.PubMed
  23. de Jong MD, Bach VC, Phan TQ, Vo MH, Tran TT, Nguyen BH, Fatal avian influenza A (H5N1) in a child presenting with diarrhea followed by coma. N Engl J Med. 2005;352:68691. DOIPubMed
  24. Gao P, Watanabe S, Ito T, Goto H, Wells K, McGregor M, Biological heterogeneity, including systemic replication in mice, of H5N1 influenza A virus isolates from humans in Hong Kong. J Virol. 1999;73:31849.PubMed
  25. Lu X, Tumpey TM, Morken T, Zaki SR, Cox NJ, Katz JM. A mouse model for the evaluation of pathogenesis and immunity to influenza A (H5N1) viruses isolated from humans. J Virol. 1999;73:590311.PubMed
  26. Hatta M, Gao P, Halfmann P, Kawaoka Y. Molecular basis for high virulence of Hong Kong H5N1 influenza A viruses. Science. 2001;293:18402. DOIPubMed
  27. Fouchier RA, Schneeberger PM, Rozendaal FW, Broekman JM, Kemink SA, Munster V, Avian influenza A virus (H7N7) associated with human conjunctivitis and a fatal case of acute respiratory distress syndrome. Proc Natl Acad Sci U S A. 2004;101:135661. DOIPubMed
  28. Puthavathana P, Auewarakul P, Charoenying PC, Sangsiriwut K, Pooruk P, Boonnak K, Molecular characterization of the complete genome of human influenza H5N1 virus isolates from Thailand. J Gen Virol. 2005;86:42333. DOIPubMed
  29. Subbarao EK, London W, Murphy BR. A single amino acid in the PB2 gene of influenza A virus is a determinant of host range. J Virol. 1993;67:17614.PubMed
  30. Naffakh N, Massin P, Escriou N, Crescenzo-Chaigne B, van der Werf S. Genetic analysis of the compatibility between polymerase proteins from human and avian strains of influenza A viruses. J Gen Virol. 2000;81:128391.PubMed
  31. Scholtissek C, Rohde W, Von Hoyningen V, Rott R. On the origin of the human influenza virus subtypes H2N2 and H3N2. Virology. 1978;87:1320. DOIPubMed
  32. Kawaoka Y, Krauss S, Webster RG. Avian-to-human transmission of the PB1 gene of influenza A viruses in the 1957 and 1968 pandemics. J Virol. 1989;63:46038.PubMed
  33. Snyder MH, Buckler-White AJ, London WT, Tierney EL, Murphy BR. The avian influenza virus nucleoprotein gene and a specific constellation of avian and human virus polymerase genes each specify attenuation of avian-human influenza A/Pintail/79 reassortant viruses for monkeys. J Virol. 1987;61:285763.PubMed
  34. Scholtissek C, Stech J, Krauss S, Webster RG. Cooperation between the hemagglutinin of avian viruses and the matrix protein of human influenza A viruses. J Virol. 2002;76:17816. DOIPubMed
  35. Garten W, Klenk HD. Understanding influenza virus pathogenicity. Trends Microbiol. 1999;7:99100. DOIPubMed
  36. Kawaoka Y, Naeve CW, Webster RG. Is virulence of H5N2 influenza viruses in chickens associated with loss of carbohydrate from the hemagglutinin? Virology. 1984;139:30316. DOIPubMed
  37. Garcia M, Crawford JM, Latimer JW, Rivera-Cruz E, Perdue ML. Heterogeneity in the haemagglutinin gene and emergence of the highly pathogenic phenotype among recent H5N2 avian influenza viruses from Mexico. J Gen Virol. 1996;77:1493504. DOIPubMed
  38. Banks J, Speidel ES, Moore E, Plowright L, Piccirillo A, Capua I, Changes in the haemagglutinin and the neuraminidase genes prior to the emergence of highly pathogenic H7N1 avian influenza viruses in Italy. Arch Virol. 2001;146:96373. DOIPubMed
  39. Suarez DL, Senne DA, Banks J, Brown IH, Essen SC, Lee CW, Recombination resulting in virulence shift in avian influenza outbreak, Chile. Emerg Infect Dis. 2004;10:6939.PubMed
  40. Pasick J, Handel K, Robinson J, Copps J, Ridd D, Hills K, Intersegmental recombination between the haemagglutinin and matrix genes was responsible for the emergence of a highly pathogenic H7N3 avian influenza virus in British Columbia. J Gen Virol. 2005;86:72731. DOIPubMed
  41. Horimoto T, Kawaoka Y. Reverse genetics provides direct evidence for a correlation of hemagglutinin cleavability and virulence of an avian influenza A virus. J Virol. 1994;68:31208.PubMed
  42. Garcia-Sastre A. Identification and characterization of viral antagonists of type I interferon in negative-strand RNA viruses. Curr Top Microbiol Immunol. 2004;283:24980.PubMed
  43. Krug RM, Yuan W, Noah DL, Latham AG. Intracellular warfare between human influenza viruses and human cells: the roles of the viral NS1 protein. Virology. 2003;309:1819. DOIPubMed
  44. Geiss GK, Salvatore M, Tumpey TM, Carter VS, Wang X, Basler CF, Cellular transcriptional profiling in influenza A virus-infected lung epithelial cells: the role of the nonstructural NS1 protein in the evasion of the host innate defense and its potential contribution to pandemic influenza. Proc Natl Acad Sci U S A. 2002;99:1073641. DOIPubMed
  45. Cheung CY, Poon LL, Lau AS, Luk W, Lau YL, Shortridge KF, Induction of proinflammatory cytokines in human macrophages by influenza A (H5N1) viruses: a mechanism for the unusual severity of human disease? Lancet. 2002;360:18317. DOIPubMed
  46. Guan Y, Poon LL, Cheung CY, Ellis TM, Lim W, Lipatov AS, H5N1 influenza: a protean pandemic threat. Proc Natl Acad Sci U S A. 2004;101:815661. DOIPubMed
  47. Kash JC, Basler CF, Garcia-Sastre A, Carter V, Billharz R, Swayne DE, Global host immune response: pathogenesis and transcriptional profiling of type A influenza viruses expressing the hemagglutinin and neuraminidase genes from the 1918 pandemic virus. J Virol. 2004;78:9499511. DOIPubMed
  48. Seo SH, Hoffmann E, Webster RG. Lethal H5N1 influenza viruses escape host anti-viral cytokine responses. Nat Med. 2002;8:9504. DOIPubMed
  49. Seo SH, Hoffmann E, Webster RG. The NS1 gene of H5N1 influenza viruses circumvents the host anti-viral cytokine responses. Virus Res. 2004;103:10713. DOIPubMed

Table

Suggested citation for this article: Neumann G, Kawaoka Y. Host range restriction and pathogenicity in the context of influenza pandemic. Emerg Infect Dis [serial on the Internet]. 2006 Jun [date cited]. http://dx.doi.org/10.3201/eid1206.051336

DOI: 10.3201/eid1206.051336

Top of Page

Table of Contents – Volume 12, Number 6—June 2006

Comments to the Authors

Please use the form below to submit correspondence to the authors or contact them at the following address:

Yoshihiro Kawaoka, Department of Pathobiological Sciences, School of Veterinary Medicine, University of Wisconsin-Madison, 2015 Linden Dr, Madison, WI 53706, USA





characters(s) remaining.

Comment submitted successfully, thank you for your feedback.

Comments to the EID Editors

Please contact the EID Editors via our Contact Form.

 

Past Issues

Select a Past Issue:

Art in Science - Selections from Emerging Infectious Diseases
Now available for order



CDC 24/7 – Saving Lives, Protecting People, Saving Money. Learn More About How CDC Works For You…

USA.gov: The U.S. Government's Official Web PortalDepartment of Health and Human Services
Centers for Disease Control and Prevention   1600 Clifton Rd. Atlanta, GA 30333, USA
800-CDC-INFO (800-232-4636) TTY: (888) 232-6348 - Contact CDC–INFO